A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Active:	Yes
Cancer Type:	Colon/Rectal Cancer	NCT ID:	NCT07221357
Trial Phases:	Phase II Phase III	Protocol IDs:	CA266-0003 (primary) 2025-523224-45 ( Other Identifier ) (OTHER: EU CT U1111-1325-6505 ( Other Identifier ) (OTHER: UTN)
Eligibility:	, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	https://clinicaltrials.gov/study/NCT07221357

Summary

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.